TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Hold” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Hold” from the thirteen research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $134.50.

A number of equities research analysts have recently weighed in on TMDX shares. Canaccord Genuity Group restated a “buy” rating and set a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research report on Wednesday. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Finally, Stifel Nicolaus increased their target price on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the period. Geode Capital Management LLC increased its holdings in TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after acquiring an additional 2,903 shares during the last quarter. Two Sigma Investments LP raised its position in shares of TransMedics Group by 54.2% in the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after purchasing an additional 223,409 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after acquiring an additional 171,810 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $72.26 on Wednesday. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $2.50 billion, a PE ratio of 16.42 and a beta of 1.89. The business has a 50-day moving average price of $71.73 and a two-hundred day moving average price of $102.68. TransMedics Group has a one year low of $60.10 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the previous year, the firm posted $0.70 EPS. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. As a group, analysts predict that TransMedics Group will post 1.88 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.